Ann: ResApp Provides Australian Adult Study Enrolment Update-RAP.AX, page-32

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 32 Last

Share
Profile

Follow
Okey-Dokey

39 Posts.

07/06/16

10:45

Post #: 17969796
Share

Originally posted by Larry73 ↑

ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has enrolled 322 adult patients (236 confirmed respiratory disease cases and 86 control cases) in its first adult study at Joondalup Health Campus. - That is an accuracy of 80% successful diagnosis, while the other 20% were identified and controlled. Incredible.

Enrolment at the Wesley Emergency Centre in Brisbane, Australia has recently started which will significantly increase the rate of enrolment and greatly expand the range of respiratory illnesses captured.

The study at the Wesley Emergency Centre is also ResApp’s first clinical site to perform electronic data collection using Apple iPads which will increase the speed of data verification and analysis. “We are very pleased with the rate of patient enrolment at Joondalup.

At that one site we are already close to achieving our initial target total enrolment of 400 adult patients and with the Wesley also recruiting patients we expect to exceed our initial target shortly,” said Dr Tony Keating, Managing Director and CEO of ResApp. “We are now looking towards the first preliminary analysis of the adult data which is on track to be released by the end of this quarter.”

This was also lovely to read:
WEC’s Director of Emergency Medicine Dr Sean Rothwell said the WEC, which was one of the biggest private emergency centres in the country, was happy to participate in the trial as it could have huge healthcare benefits. It has the potential to become an efficient diagnostic tool for emergency centres around the country and the world, he said.

Great times ahead, this month is going to be huge

Expand

The 236 confirmed respiratory disease cases and the 86 control cases means that they have enrolled 236 patients with a respiratory disease and 86 that don't have one; this is not a reporting of results! For those 322 patients, they will compare the ResApp diagnosis to their known conditions, and hopefully they will match well!

RAP Price at posting: 38.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

EBR

EBR Systems' heart pacing device on-target to reach the US market

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

SKS

SKS secures $20M for extension works on Melbourne data centre